HER2+ from patent application: CCR5 binding agent
Post# of 155142
(Total Views: 3172)
Posted On: 03/31/2025 8:45:04 PM
HER2+ from patent application: CCR5 binding agent for treatment of CCR5 positive metastatic cancer.
Jan. 2021
One of the listed patients:
EXAMPLE 4 LERONLIMAB TREATMENT OF METASTATIC HER2+ BREAST CANCER
This subject, Patient A, is a 78-year-old female with a diagnosis of metastatic breast cancer, stage IV.
The subject previously received Taxotere/Herceptin/Pertuzumab as frontline therapy for metastatic HER2 positive breast cancer.
She had partial response for her systemic disease, but then developed diffuse brain metastases (systemic disease stable).
She completed whole-brain radiation therapy and continues on Herceptin and Pertuzumab.
She has neuropathy and residual side effects from chemotherapy, which limits use of current second-line options due to concern for side effects.
Leronlimab (PRO 140) was requested in an attempt to achieve disease control and prolong chemotherapy-free interval as this patient may not be able to tolerate chemotherapy side effects.
The subject is receiving weekly injections of 700mg leronlimab (PRO 140) (Table 5).
Table 5: Leronlimab (PRO 140) Administration Schedule Single Patient Emergency Use IND Subject Visit Date Study Treatment Administration Screening NA Treatment 1 DAY 1 Leronlimab (PRO 140) 700 mg Treatment 2 DAY 10 Leronlimab (PRO 140) 700 mg Treatment 3 DAY 17 Leronlimab (PRO 140) 700 mg Treatment 4 DAY 24 Leronlimab (PRO 140) 700 mg Treatment 5 DAY 35 Leronlimab (PRO 140) 700 mg 43WO 2021/146323 PCT/US2021/013289 Treatment 6 DAY 46 Leronlimab (PRO 140) 700 mg
Approximately four weeks following the initial treatment, a CT scan was conducted and the results indicated no signs of new metastatic spots in the liver, lung and brain during the treatment with leronlimab, as compared to the CT scan results obtained approximately 6 weeks prior to the initiation of treatment.
Approximately two months following the initial treatment, no new metastasis was detectable in the brain after treatment with leronlimab being the only treatment the subject was receiving to treat brain metastasis.
Prior to enrolling in the trial, the patient had 18 identifiable tumor spots in the brain.
At approximately two months following the start of weekly 700 mg doses of leronlimab, only three lesions were identifiable, as detected by MRI.
Furthermore, the treatment resulted in a 56% reduction in tumor volume of the largest brain tumor identified in the subject's brain at the initiation of treatment.
Approximately ten weeks following the initiation of treatment, the subject's CTC and EMT counts were measured, and zero CTCs and zero EMTs were identified.
________
Patent applications & Patents.
1600 data report & now mTNBC news right @ 48 months ---- " cancer free ".
Wow! ....
Jan. 2021
One of the listed patients:
EXAMPLE 4 LERONLIMAB TREATMENT OF METASTATIC HER2+ BREAST CANCER
This subject, Patient A, is a 78-year-old female with a diagnosis of metastatic breast cancer, stage IV.
The subject previously received Taxotere/Herceptin/Pertuzumab as frontline therapy for metastatic HER2 positive breast cancer.
She had partial response for her systemic disease, but then developed diffuse brain metastases (systemic disease stable).
She completed whole-brain radiation therapy and continues on Herceptin and Pertuzumab.
She has neuropathy and residual side effects from chemotherapy, which limits use of current second-line options due to concern for side effects.
Leronlimab (PRO 140) was requested in an attempt to achieve disease control and prolong chemotherapy-free interval as this patient may not be able to tolerate chemotherapy side effects.
The subject is receiving weekly injections of 700mg leronlimab (PRO 140) (Table 5).
Table 5: Leronlimab (PRO 140) Administration Schedule Single Patient Emergency Use IND Subject Visit Date Study Treatment Administration Screening NA Treatment 1 DAY 1 Leronlimab (PRO 140) 700 mg Treatment 2 DAY 10 Leronlimab (PRO 140) 700 mg Treatment 3 DAY 17 Leronlimab (PRO 140) 700 mg Treatment 4 DAY 24 Leronlimab (PRO 140) 700 mg Treatment 5 DAY 35 Leronlimab (PRO 140) 700 mg 43WO 2021/146323 PCT/US2021/013289 Treatment 6 DAY 46 Leronlimab (PRO 140) 700 mg
Approximately four weeks following the initial treatment, a CT scan was conducted and the results indicated no signs of new metastatic spots in the liver, lung and brain during the treatment with leronlimab, as compared to the CT scan results obtained approximately 6 weeks prior to the initiation of treatment.
Approximately two months following the initial treatment, no new metastasis was detectable in the brain after treatment with leronlimab being the only treatment the subject was receiving to treat brain metastasis.
Prior to enrolling in the trial, the patient had 18 identifiable tumor spots in the brain.
At approximately two months following the start of weekly 700 mg doses of leronlimab, only three lesions were identifiable, as detected by MRI.
Furthermore, the treatment resulted in a 56% reduction in tumor volume of the largest brain tumor identified in the subject's brain at the initiation of treatment.
Approximately ten weeks following the initiation of treatment, the subject's CTC and EMT counts were measured, and zero CTCs and zero EMTs were identified.
________
Patent applications & Patents.
1600 data report & now mTNBC news right @ 48 months ---- " cancer free ".
Wow! ....
(17)
(0)